Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis.

Liu, Yuting; Li, Weixia; Chen, Yu; Wang, Xin

Liu, Yuting; Li, Weixia; Chen, Yu; Wang, Xin.

Afiliación

Liu Y; Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine/the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Li W; The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Chen Y; Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine/the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Wang X; Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine/the Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. xin.wang@njucm.edu.cn.

Endocrine ; 83(2): 322-329, 2024 Feb.

Article en En | MEDLINE | ID: mdl-37658243

Asunto(s)

Diabetes Mellitus Tipo 1; Humanos; Diabetes Mellitus Tipo 1/tratamiento farmacológico; Péptido C; Anticuerpos Monoclonales Humanizados; Anticuerpos Monoclonales/uso terapéutico; Insulina/uso terapéutico

Palabras clave

Anti-CD3; Immunotherapy; Meta-analysis; Otelixizumab; Teplizumab; Type 1 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Endocrine Asunto de la revista: ENDOCRINOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google